Gilead Sciences CDR (CAD Hedged) (GILD : TSX)
Common Stock
Follow GILD
GILD
Gilead Sciences CDR (CAD Hedged)
WealthAwesomePerformance
1 Day
+1.67%
1 Week
-0.84%
1 Month
+12.09%
YTD
+36.88%
The Tuesday Stock Pick · free, every tuesday morning. One Canadian stock and the case for it.
Key Statistics
Market Cap
$174.33B
52W High
$35.36
52W Low
$23.55
P/E Ratio
-
50 Day MA
$30.75
200 Day MA
$28.53
Beta
-
Dividend Yield
9.64%
Performance history
GILD returns since 2025
Gilead Sciences CDR (CAD Hedged) has traded since Dec 2025 in our data. Its deepest fall was −22.4% (Feb 2026 to Jun 2026).
1 year / yr
—
3 years / yr
—
5 years / yr
—
10 years / yr
—
Calendar-year returns
- 2025*−3.0%
- 2026*+34.9%
* Partial year (first year of data, or year to date).
$10,000 invested in GILD
- 2025 (start of our data)$13,079
- All-time high in our data
- $35 on Nov 4, 2026 · now −2.8%
Total-return basis using adjusted daily closes from the Toronto Stock Exchange and TSX Venture (dividends and splits folded in), Dec 2025 to Nov 2026. Past returns do not predict future ones.
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 11/9/2026 | $33.47 | $34.15 | $33.47 | $34.11 | $34.11 | 4,232 |
| 11/6/2026 | $33.30 | $33.79 | $33.29 | $33.55 | $33.55 | 7,031 |
| 11/5/2026 | $35.36 | $35.36 | $33.72 | $33.72 | $33.72 | 6,771 |
| 11/4/2026 | $34.63 | $35.22 | $34.40 | $35.11 | $35.11 | 7,626 |
| 11/3/2026 | $34.30 | $34.39 | $33.82 | $33.82 | $33.82 | 2,962 |
| 11/2/2026 | $34.36 | $34.40 | $33.62 | $34.40 | $34.40 | 12,249 |
| 10/30/2026 | $34.42 | $35.23 | $34.17 | $34.35 | $34.35 | 27,548 |
| 10/29/2026 | $32.64 | $33.30 | $32.40 | $33.24 | $33.24 | 13,461 |
| 10/28/2026 | $31.85 | $32.08 | $31.85 | $32.06 | $32.06 | 3,090 |
| 10/27/2026 | $31.71 | $31.97 | $31.42 | $31.95 | $31.95 | 4,698 |
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
31.6%
Annualized
90-Day Vol
29.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$40.78
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$36.20 | C$32.46 – C$40.37 |
| 60 trading days | C$38.42 | C$32.94 – C$44.82 |
| 90 trading days | C$40.78 | C$33.77 – C$49.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Gilead Sciences CDR (CAD Hedged)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Financials
- Revenue (TTM)
- $0
- EBITDA
- -
- Profit Margin
- 0.00%
- ROE (TTM)
- 4049.30%
- EPS (Diluted)
- 0.00
- Book Value
- -
Classification
- Sector
- Health Care
Recent Dividends
$0.1649CAD
Ex: Sep 15, 2026
Pay: Oct 7
$0.1670CAD
Ex: Mar 13, 2026
$0.1601CAD
Ex: Dec 15, 2025
$0.1633CAD
Ex: Sep 15, 2025
$0.1640CAD
Ex: Jun 13, 2025
Free newsletter
The Tuesday Stock Pick
One Canadian stock and the case for it
- The name with the biggest gap to analyst targets
- The chart, insider buying and what is driving it
- A plain-English bottom line, no hype
Explore More
Common Questions About GILD
Market movers
Recent TSX movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| PNC-A | Postmedia Network Canada Corp | $0.14 | +38.10% |
| GFR | Greenfire Resources Ltd. | $10.94 | +37.96% |
| ADCO | Adcore Inc | $0.17 | +21.43% |
| DND | Dye & Durham Ltd | $1.96 | +20.99% |
| COPR | Coppernico Metals Inc. | $0.38 | +20.97% |
| ELEF | Silver Elephant Mining Corp | $0.32 | +20.75% |
| FT | Fortune Minerals Limited | $0.09 | +20.00% |
| SAM | Starcore International Mines Ltd | $0.32 | +18.52% |